What do systematic reviews say?

Neurohormones vs placebo

The review found no eligible studies for this question.

• Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neurohormones vs placebo

It is very uncertain whether neurohormones changes adverse effects compared with placebo (very low certainty).

• Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
  RR 0.58 [0.38, 0.89]
  10 studies · 863 participants
  Very low

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1398 participants
  Moderate

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1398 participants
  Moderate

Educational or behavioural interventions for patients vs usual care

Educational or behavioural interventions for patients showed no clear difference in blood pressure target achievement compared with usual care (moderate certainty).

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  OR 1.34 [0.7, 2.59]
  3 studies · 266 participants
  Moderate

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 33762 participants
  Low

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 495 participants
  Moderate

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Low

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 127 participants
  Moderate

Honey vs no treatment

Honey led to lower oral mucositis (moderate to severe) compared with no treatment; GRADE not reported.

• Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes

  Median 28 days
  RR 0.48 [0.31, 0.74]
  3 studies
  GRADE not reported

Honey vs no treatment

Honey led to lower oral mucositis (any severity) compared with no treatment; GRADE not reported.

• Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes

  Median 28 days
  RR 0.7 [0.56, 0.88]
  3 studies
  GRADE not reported

Honey vs no treatment

Honey led to lower oral mucositis (severe) compared with no treatment; GRADE not reported.

• Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes

  Median 28 days
  RR 0.26 [0.13, 0.52]
  3 studies
  GRADE not reported

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Summary of findings table (subcomparison 2): second‐line… probably leads to lower overall survival compared with control intervention alone (moderate certainty).

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  HR 0.71 [0.54, 0.94]
  4 studies · 769 participants
  Moderate

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

Summary of findings table (subcomparison 2): second‐line… may leads to lower progression‐free survival compared with control intervention alone (low certainty).

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  HR 0.51 [0.29, 0.9]
  3 studies · 677 participants
  Low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes

  Minimum 2 weeks
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes
  No data available (no included studies)
  0 studies
  No studies found

Any antimicrobial mouthwash and/or nasal spray (alone or in combination), at any concentration, delivered to healthcare workers, with or without the same intervention given to the patients with COVID-19 vs No treatment or saline or water

The review found no eligible studies for this question.

• Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating… 2020 · Cochrane All outcomes

  Minimum 2 weeks
  No data available (no included studies)
  0 studies
  No studies found